Literature DB >> 28484843

HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature.

Laura Larnaudie1, Eva Compérat1, Pierre Conort2, Justine Varinot3.   

Abstract

We report the case of an 81-year-old patient with a pleomorphic giant cell adenocarcinoma of the prostate. After diagnosis, he rapidly developed bone metastasis and died within 1 year. This variant of acinar adenocarcinoma is extremely rare and prognosis is poor. This entity has been included into the 2016 WHO classification. The principal differential diagnosis is urothelial carcinoma. To assess the prostatic origin, routine immunohistochemistry can be problematic. Loss of epitopes in this poorly differentiated entity can occur, such as loss of expression of PSA and p504s. We recently described a very sensitive and specific marker of prostate cancer, HOXB13, which once again has proven to be highly specific and sensitive. This is the first description of a pleomorphic giant cell prostate cancer expressing HOXB13.

Entities:  

Keywords:  Adenocarcinoma; Giant cell; HOXB13; Pleomorphic; Prostate cancer

Mesh:

Substances:

Year:  2017        PMID: 28484843     DOI: 10.1007/s00428-017-2134-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  8 in total

1.  Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases.

Authors:  Anil V Parwani; Mehsati Herawi; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2006-10       Impact factor: 6.394

2.  Pleomorphic giant cell carcinoma of the prostate.

Authors:  Antonio Lopez-Beltran; John N Eble; David G Bostwick
Journal:  Arch Pathol Lab Med       Date:  2005-05       Impact factor: 5.534

Review 3.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Authors:  Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

4.  HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.

Authors:  Valeria Barresi; Antonio Ieni; Roberta Cardia; Luana Licata; Enrica Vitarelli; Luca Reggiani Bonetti; Giovanni Tuccari
Journal:  APMIS       Date:  2015-11-20       Impact factor: 3.205

5.  HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin.

Authors:  Justine Varinot; Adéline Furudoï; Sarah Drouin; Véronique Phe; Raphaele Renard Penna; Morgan Roupret; Marc-Olivier Bitker; Olivier Cussenot; Eva Compérat
Journal:  Virchows Arch       Date:  2016-03-01       Impact factor: 4.064

Review 6.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.

Authors:  Holger Moch; Antonio L Cubilla; Peter A Humphrey; Victor E Reuter; Thomas M Ulbright
Journal:  Eur Urol       Date:  2016-02-28       Impact factor: 20.096

7.  Sarcomatoid Urothelial Carcinoma of the Bladder: Analysis of 28 Cases With Emphasis on Clinicopathologic Features and Markers of Epithelial-to-Mesenchymal Transition.

Authors:  Joseph Sanfrancesco; Jesse K McKenney; Mariah Z Leivo; Sounak Gupta; Paul Elson; Donna E Hansel
Journal:  Arch Pathol Lab Med       Date:  2016-03-31       Impact factor: 5.534

8.  HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin.

Authors:  Justine Varinot; Olivier Cussenot; Morgan Roupret; Pierre Conort; Marc-Olivier Bitker; Emmanuel Chartier-Kastler; Liang Cheng; Eva Compérat
Journal:  Virchows Arch       Date:  2013-10-22       Impact factor: 4.064

  8 in total
  4 in total

1.  HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder.

Authors:  Valeria Barresi
Journal:  Virchows Arch       Date:  2018-06-21       Impact factor: 4.064

2.  Letter to the editor: reply to Valeria Barresi "HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder".

Authors:  Justine Varinot; Eva Compérat
Journal:  Virchows Arch       Date:  2018-06-22       Impact factor: 4.064

3.  DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.

Authors:  Tamara L Lotan; Harsimar B Kaur; Abdullah M Alharbi; Colin C Pritchard; Jonathan I Epstein
Journal:  Histopathology       Date:  2019-04-01       Impact factor: 5.087

4.  Portrait of Tissue-Specific Coexpression Networks of Noncoding RNAs (miRNA and lncRNA) and mRNAs in Normal Tissues.

Authors:  Claudia Cava; Gloria Bertoli; Isabella Castiglioni
Journal:  Comput Math Methods Med       Date:  2019-09-03       Impact factor: 2.238

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.